Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain

Anne Kessinger, Henry M. Lemon, John F. Foley

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty‐nine patients with grade III or IV astrocytomas were treated with 1,3 bis(2‐chloroethyl)‐1‐nitrosourea (BCNU), 75–100 mg/M2 intravenously (IV) for two consecutive days every four to six weeks, in an effort to improve the quality and length of their survival following surgical resection. Twenty‐one of these patients received adjunctive chemotherapy as soon as they recovered from surgery and 18 received concomitant adjunctive radiation therapy as well. Eight patients were treated with radiation therapy after surgery, and BCNU was not added until evidence of tumor growth appeared. BCNU was discontinued and the epipodophyllotoxin. VM‐26, was given at a dose of 100 mg/M2 IV weekly when further tumor growth occurred. Patients receiving adjuvant chemotherapy had a shorter mean and median survival than patients receiving BCNU when progression appeared following radiation therapy. Six patients with progressive disease following surgical resection and radiation therapy for grade 11 astrocytoma were treated with BCNU. Improvement or stabilization of neurologic symptoms occurred in four of these patients. This trial of lower‐dose BCNU therapy produced survival rates similar to higher‐dose studies and permitted fewer physician visits by the patient.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalJournal of Surgical Oncology
Volume10
Issue number6
DOIs
StatePublished - 1978

Fingerprint

Astrocytoma
Adjuvant Chemotherapy
Carmustine
Brain
Radiotherapy
Podophyllotoxin
Survival
Growth
Neurologic Manifestations
Neoplasms
Survival Rate
Physicians
Drug Therapy

Keywords

  • BCNU
  • VM‐26
  • brain tumor

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain. / Kessinger, Anne; Lemon, Henry M.; Foley, John F.

In: Journal of Surgical Oncology, Vol. 10, No. 6, 1978, p. 543-547.

Research output: Contribution to journalArticle

Kessinger, Anne ; Lemon, Henry M. ; Foley, John F. / Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain. In: Journal of Surgical Oncology. 1978 ; Vol. 10, No. 6. pp. 543-547.
@article{f022e87eb2464674a1afed6aa77f6962,
title = "Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain",
abstract = "Twenty‐nine patients with grade III or IV astrocytomas were treated with 1,3 bis(2‐chloroethyl)‐1‐nitrosourea (BCNU), 75–100 mg/M2 intravenously (IV) for two consecutive days every four to six weeks, in an effort to improve the quality and length of their survival following surgical resection. Twenty‐one of these patients received adjunctive chemotherapy as soon as they recovered from surgery and 18 received concomitant adjunctive radiation therapy as well. Eight patients were treated with radiation therapy after surgery, and BCNU was not added until evidence of tumor growth appeared. BCNU was discontinued and the epipodophyllotoxin. VM‐26, was given at a dose of 100 mg/M2 IV weekly when further tumor growth occurred. Patients receiving adjuvant chemotherapy had a shorter mean and median survival than patients receiving BCNU when progression appeared following radiation therapy. Six patients with progressive disease following surgical resection and radiation therapy for grade 11 astrocytoma were treated with BCNU. Improvement or stabilization of neurologic symptoms occurred in four of these patients. This trial of lower‐dose BCNU therapy produced survival rates similar to higher‐dose studies and permitted fewer physician visits by the patient.",
keywords = "BCNU, VM‐26, brain tumor",
author = "Anne Kessinger and Lemon, {Henry M.} and Foley, {John F.}",
year = "1978",
doi = "10.1002/jso.2930100611",
language = "English (US)",
volume = "10",
pages = "543--547",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Sequential and adjuvant chemotherapy for malignant astrocytoma of the brain

AU - Kessinger, Anne

AU - Lemon, Henry M.

AU - Foley, John F.

PY - 1978

Y1 - 1978

N2 - Twenty‐nine patients with grade III or IV astrocytomas were treated with 1,3 bis(2‐chloroethyl)‐1‐nitrosourea (BCNU), 75–100 mg/M2 intravenously (IV) for two consecutive days every four to six weeks, in an effort to improve the quality and length of their survival following surgical resection. Twenty‐one of these patients received adjunctive chemotherapy as soon as they recovered from surgery and 18 received concomitant adjunctive radiation therapy as well. Eight patients were treated with radiation therapy after surgery, and BCNU was not added until evidence of tumor growth appeared. BCNU was discontinued and the epipodophyllotoxin. VM‐26, was given at a dose of 100 mg/M2 IV weekly when further tumor growth occurred. Patients receiving adjuvant chemotherapy had a shorter mean and median survival than patients receiving BCNU when progression appeared following radiation therapy. Six patients with progressive disease following surgical resection and radiation therapy for grade 11 astrocytoma were treated with BCNU. Improvement or stabilization of neurologic symptoms occurred in four of these patients. This trial of lower‐dose BCNU therapy produced survival rates similar to higher‐dose studies and permitted fewer physician visits by the patient.

AB - Twenty‐nine patients with grade III or IV astrocytomas were treated with 1,3 bis(2‐chloroethyl)‐1‐nitrosourea (BCNU), 75–100 mg/M2 intravenously (IV) for two consecutive days every four to six weeks, in an effort to improve the quality and length of their survival following surgical resection. Twenty‐one of these patients received adjunctive chemotherapy as soon as they recovered from surgery and 18 received concomitant adjunctive radiation therapy as well. Eight patients were treated with radiation therapy after surgery, and BCNU was not added until evidence of tumor growth appeared. BCNU was discontinued and the epipodophyllotoxin. VM‐26, was given at a dose of 100 mg/M2 IV weekly when further tumor growth occurred. Patients receiving adjuvant chemotherapy had a shorter mean and median survival than patients receiving BCNU when progression appeared following radiation therapy. Six patients with progressive disease following surgical resection and radiation therapy for grade 11 astrocytoma were treated with BCNU. Improvement or stabilization of neurologic symptoms occurred in four of these patients. This trial of lower‐dose BCNU therapy produced survival rates similar to higher‐dose studies and permitted fewer physician visits by the patient.

KW - BCNU

KW - VM‐26

KW - brain tumor

UR - http://www.scopus.com/inward/record.url?scp=0018248750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018248750&partnerID=8YFLogxK

U2 - 10.1002/jso.2930100611

DO - 10.1002/jso.2930100611

M3 - Article

C2 - 215846

AN - SCOPUS:0018248750

VL - 10

SP - 543

EP - 547

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 6

ER -